Suppr超能文献

腹腔注射骨化三醇对钙和甲状旁腺激素的影响。

The effects of intraperitoneal calcitriol on calcium and parathyroid hormone.

作者信息

Delmez J A, Dougan C S, Gearing B K, Rothstein M, Windus D W, Rapp N, Slatopolsky E

出版信息

Kidney Int. 1987 Mar;31(3):795-9. doi: 10.1038/ki.1987.68.

Abstract

Parathyroid suppression by intraperitoneal calcitriol (1,25(OH)2D3) during peritoneal dialysis. The purpose of this study was to determine if parathyroid hormone (PTH) suppression could be achieved by increasing calcium mass transfer (Ca MT) with high dialysate Ca (4 mEq/liter) or via intraperitoneal (i.p.) 1,25(OH)2D3 in patients undergoing continuous ambulatory peritoneal dialysis. Eleven patients were dialyzed for two months with standard Ca dialysate (3.5 mEq/liter) followed by two months with 4.0 mEq/liter Ca, then by three months of i.p. 1,25(OH)2D3. During the latter period, patients were randomized to groups whose dialysate contained either 3.5 mEq/liter or 4.0 mEq/liter Ca. We found that 4.0 mEq/liter Ca dialysate more than doubled Ca MT (37 +/- 17 mg/day to 84 +/- 6 mg/day) leading to a modest fall (P less than 0.05) in PTH levels (84 +/- 5.5% of controls). Ionized calcium levels did not change. With i.p. 1,25(OH)2D3, however, ionized calcium rose significantly (P less than 0.001) leading to a decline in PTH levels to 53.9 +/- 7.9% of control values. Serum 1,25(OH)2D3 levels rose from undetectable to 47.7 +/- 7.2 pg/dl (normal range 20 to 35). These studies indicate that increasing Ca MT using a 4.0 mEq/liter Ca dialysate leads to a small reduction in PTH concentrations. On the other hand, i.p. 1,25(OH)2D3 is well absorbed into the systemic circulation, raises ionized calcium levels, and leads to a marked suppression of PTH. Thus, i.p. 1,25(OH)2D3 may be a simple and effective means to suppress secondary hyperparathyroidism in patients undergoing CAPD.

摘要

腹膜透析期间腹腔内注射骨化三醇(1,25-二羟维生素D3)对甲状旁腺的抑制作用。本研究的目的是确定在持续非卧床腹膜透析患者中,通过高钙透析液(4 mEq/升)增加钙转运量(Ca MT)或通过腹腔内注射1,25-二羟维生素D3是否能实现甲状旁腺激素(PTH)的抑制。11例患者先用标准钙透析液(3.5 mEq/升)透析2个月,然后用4.0 mEq/升钙透析液透析2个月,随后进行3个月的腹腔内注射1,25-二羟维生素D3。在后一阶段,患者被随机分为两组,透析液钙含量分别为3.5 mEq/升或4.0 mEq/升。我们发现,4.0 mEq/升钙透析液使Ca MT增加了一倍多(从37±17毫克/天增至84±6毫克/天),导致PTH水平适度下降(P<0.05)(降至对照组的84±5.5%)。离子钙水平未发生变化。然而,腹腔内注射1,25-二羟维生素D3后,离子钙显著升高(P<0.001),导致PTH水平降至对照组值的53.9±7.9%。血清1,25-二羟维生素D3水平从检测不到升至47.7±7.2 pg/dl(正常范围20至35)。这些研究表明,使用4.0 mEq/升钙透析液增加Ca MT会使PTH浓度略有降低。另一方面,腹腔内注射1,25-二羟维生素D3能很好地被吸收进入体循环,提高离子钙水平,并导致PTH显著抑制。因此,腹腔内注射1,25-二羟维生素D3可能是抑制持续非卧床腹膜透析患者继发性甲状旁腺功能亢进的一种简单有效的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验